-
1.发明授权公开(公告)号：US08846945B2
公开(公告)日：2014-09-30
申请号：US13462115
申请日：2012-05-02
IPC分类号： C07D257/04
CPC分类号： A61K31/41 , A61K31/4439 , A61K31/497 , A61K31/5377 , C07D241/12 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D491/10 , C07D491/107 , C07D498/08
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5和R 6如本文所定义。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
2.发明授权公开(公告)号：US08841336B2
公开(公告)日：2014-09-23
申请号：US13240249
申请日：2011-09-22
IPC分类号： A61K31/41 , C07D213/12 , C07D471/04 , C07D401/10 , C07D405/12 , C07D257/04 , C07D409/14 , C07D401/14
CPC分类号： C07D257/04 , C07D401/10 , C07D401/14 , C07D405/12 , C07D409/14 , C07D413/12 , C07D471/04
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5，R 6 R 7和R 8如本文所定义 。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
3.发明授权Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists 有权噻唑和恶唑取代的芳基酰胺作为P2X3和P2X2 / 3拮抗剂公开(公告)号：US07786110B2
公开(公告)日：2010-08-31
申请号：US11983225
申请日：2007-11-08
IPC分类号： C07D417/12 , C07D277/30 , C07D263/32 , C07D413/12 , C07D277/66 , A61K31/497 , A61K31/5355 , A61K31/428 , A61K31/426 , A61K31/421 , A61K31/541 , A61P13/00 , A61P11/00 , C07D409/14 , C07D417/10
CPC分类号： C07D401/14 , C07D263/32 , C07D277/30 , C07D277/66
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R1是式A或式B的基团，X，R2，R3，R4，R5，R6，Ra和Rb如本文所定义。 还提供了使用该化合物治疗由P2X3和/或P2X2 / 3受体拮抗剂介导的疾病的方法和制备本发明化合物的方法。
-
公开(公告)号：US20090170874A1
公开(公告)日：2009-07-02
申请号：US12317017
申请日：2008-12-17
IPC分类号： A61K31/497 , C07D403/12 , C07D401/14 , C07D249/04 , A61K31/4192
CPC分类号： C07D403/12 , C07D249/06 , C07D401/14
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted triazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的三唑基，R 2，R 3，R 4，R 5，R 6，R 7和R 8如本文所定义。 还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
5.发明申请公开(公告)号：US20090163502A1
公开(公告)日：2009-06-25
申请号：US12317026
申请日：2008-12-17
IPC分类号： A61K31/5377 , A61K31/4965 , A61K31/44 , A61K31/41 , C07D413/12 , C07D401/14 , C07D401/10 , C07D257/00 , C07D405/10
CPC分类号： C07D257/04 , C07D401/10 , C07D401/14 , C07D405/12 , C07D409/14 , C07D413/12 , C07D471/04
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5，R 6 R 7和R 8如本文所定义 。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
6.发明授权公开(公告)号：US09173861B2
公开(公告)日：2015-11-03
申请号：US13359330
申请日：2012-01-26
申请人： Li Chen , Lichun Feng , Minmin Yang , Michael Patrick Dillon , Yingjie Lai
发明人： Li Chen , Lichun Feng , Minmin Yang , Michael Patrick Dillon , Yingjie Lai
IPC分类号： A61K31/166 , A61K31/497 , A61K31/4427 , A61K31/444 , A61K31/4436 , A61K31/4439 , C07D417/14 , C07C233/69 , A61K31/433
CPC分类号： C07D417/14 , A61K31/166 , A61K31/433 , A61K31/4427 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/497 , C07D285/06 , C07D417/12
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted thiadiazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的噻二唑基，R 2，R 3，R 4，R 5，R 6，R 7和R 8如本文所定义。 还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
7.发明授权公开(公告)号：US08193368B2
公开(公告)日：2012-06-05
申请号：US12583325
申请日：2009-08-18
IPC分类号： C07D257/04
CPC分类号： A61K31/41 , A61K31/4439 , A61K31/497 , A61K31/5377 , C07D241/12 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D491/10 , C07D491/107 , C07D498/08
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5和R 6如本文所定义。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
8.发明申请OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS 有权OXAZOLONE和吡咯烷酮取代的ARYLAMIDES作为P2X3和P2X2 / 3拮抗剂公开(公告)号：US20100324069A1
公开(公告)日：2010-12-23
申请号：US12820660
申请日：2010-06-22
申请人： Li Chen , Michael Patrick Dillon , Lichun Feng , Minmin Yang
发明人： Li Chen , Michael Patrick Dillon , Lichun Feng , Minmin Yang
IPC分类号： A61K31/497 , C07D413/12 , A61P29/00
CPC分类号： A61K31/497 , C07D207/27 , C07D233/32 , C07D263/20 , C07D401/14 , C07D403/12 , C07D407/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D473/00
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中X，Y，R 1，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义。 还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
9.发明申请公开(公告)号：US20090326220A1
公开(公告)日：2009-12-31
申请号：US12583325
申请日：2009-08-18
IPC分类号： C07D257/04 , C07D417/12 , C07D413/12 , C07D403/14 , C07D403/12 , C07D401/12 , C07D405/12
CPC分类号： A61K31/41 , A61K31/4439 , A61K31/497 , A61K31/5377 , C07D241/12 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D491/10 , C07D491/107 , C07D498/08
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5和R 6如本文所定义。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
10.发明授权公开(公告)号：US07595405B2
公开(公告)日：2009-09-29
申请号：US11823808
申请日：2007-06-28
IPC分类号： C07D257/04
CPC分类号： A61K31/41 , A61K31/4439 , A61K31/497 , A61K31/5377 , C07D241/12 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D491/10 , C07D491/107 , C07D498/08
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5和R 6如本文所定义。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.046 秒)
